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CHROMIUM: RISE AND SHINE IN PERITONEAL DIALYSIS PATIENTS?

Guido Filler,1,2,3,4* and Christopher McIntyre1,2,4

Some trace elements are altered with chronic kidney disease. Selenium, zinc, and manganese tend to be wasted, and there is growing
evidence that selenium deficiency is associated with mortality
on dialysis. Other trace elements accumulate, such as chromium,
cobalt, lead, molybdenum, and vanadium. The highest chromium
levels are found in dialysis patients. The dialysis modality may
further affect these levels, especially in hemodialysis patients,
where even small contaminations in the dialysis feed water may
lead to a concentration gradient that increases the concentration
of certain trace elements. Chromium levels in peritoneal dialysis
(PD) patients have been understudied. A single cross-sectional
study found substantially higher chromium levels in PD patients.
In that study, the chromium concentration in the spent dialysate
decreased substantially, suggesting that PD fluid could be a source
of chromium. Chromium-lactate complexes may have been formed,
which are easily absorbed. In our center, we observed a decrease
in chromium level when using physiological PD fluids. This review
discusses the potential mechanisms and raises the question of
whether this accumulation of chromium is unlikely to be associated
with a beneficial outcome.
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hromium (Cr, atomic number 24) is well known as an additive for steel alloys to create shiny metals and to prevent
rusting. Metallic Cr does not occur in nature but is found in
compounds, in a variety of valence states (1–2). Sources of
exposure in humans include air, food, and water, with food
and especially water being the main sources (2,3). Chromium
concentrations in drinking water may be highly variable (4).
Hexavalent Cr easily enters cells through facilitated uptake,
and its reduction from Cr (VI) to Cr (III) creates free radicals
(2). It is distributed to, and accumulated by, the erythrocyte
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while the highest concentrations of Cr are found in the
kidney and liver. Chromium is highly protein-bound and is
slowly excreted via the kidneys, by tubular secretion (4).
Chromium is carcinogenic, as inhalation has been shown to
cause lung cancer in humans, and exposure has been shown
to cause tumors in the stomach, intestinal tract, and lung in
animals (2). Depending on the route of exposure, trivalent
and hexavalent Cr are also associated with gastrointestinal,
immunological, hematological (such as anemia), reproductive,
and developmental potentially devastating effects (4). While
accumulation of Cr occurs in earlier states of chronic kidney
disease (CKD) (4), Tonelli et al. have recently reported that Cr
accumulates substantially in hemodialysis (HD) patients (5,6).
This association was confirmed by measuring trace elements
in the hair of adult HD patients (7). Chromium also accumulates substantially in bone of dialysis patients (8). Data from
peritoneal dialysis (PD) patients have been scant.
In that context we are delighted to see a recent study of
169 chronic dialysis patients from 3 Israeli centers in this
edition of Peritoneal Dialysis International, which included
21 PD patients. The median (interquartile range) serum Cr
level was significantly higher in patients treated with PD
than in patients treated with HD: 5.00 (3.24 – 6.15) versus
1.83 (1.29 – 2.45) μg/L, p < 0.001. The association with PD
became even stronger when using a multivariate regression
model, with an odds ratio (OR) of 11.87 (95% confidence
interval [CI] 2.85 – 49.52, p = 0.001). These findings remained
significant after adjusting for age, gender, diabetes status,
smoking, dialysis vintage, use of diuretics, and residual renal
function (9). As all the patients came from the same area and
had the same access to municipal drinking water, the authors
did not adjust for the water Cr content (also assumed that
mains rather than purchased bottled water was the main source
of hydration). They checked the HD water for Cr and it was
found to be below the American Association for Advancement
of Medical Instrumentation (AAMI) standards. A particular
strength of the study is the additional measurement of Cr in
fresh and spent PD solutions, though only in 5 of the patients.
Perhaps the most striking finding was the fact that the Cr
concentration in the PD solutions decreased with treatment
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• Death and, at lethal doses, respiratory effects such as
pleural effusion, pulmonary edema, bronchitis, and
bronchopneumonia.
• Cardiovascular effects such as cardiopulmonary arrest, and
a drop in cardiac output, heart rate, and blood pressure.
• Lung cancer.
• Gastrointestinal effects from Cr in drinking water such
as oral ulcer, diarrhea, abdominal pain, indigestion, and
vomiting.
• Musculoskeletal effects such as rhabdomyolysis.
• Hematological effects including leukocytosis and immature
neutrophils.

Figure 1 — Chromium levels in a child who was converted from HD to
PD using high-dose CCPD with Physioneal. HD = hemodialysis; PD =
peritoneal dialysis; CCPD = continuous cycling PD.

• Hepatic effects such as the development of jaundice, and
increased bilirubin, serum lactic dehydrogenase, alanine and
aspartate aminotransferase, and γ-glutamyl transferase.
• Direct renal effects such as renal failure characterized
by proteinuria, hematuria and anuria, necrosis of renal
tubules, oliguria, and destruction of the tubular epithelium
of the kidneys.
• Chromium supplementation has also been associated with
weight loss.
Many, but not all of these Cr-related issues, are observed
in renal patients. Associations also do not infer causality. In
Tonelli’s study, death and cardiovascular risk were associated
with essential trace element deficiencies, but not with Cr elevation (5,6). Nonetheless, this accumulation of Cr is unlikely to
elicit a beneficial adaptive response. What should be done
about his accumulation of Cr in PD patients? Based on the
data provided, absorption of Cr from the dialysate clearly is a
possibility. If so, we need to compare the findings with those
in patients who are being treated with physiologic solutions.
If Cr concentrations do not decrease in the spent fluid, this
may be a powerful argument for the use of these solutions.
In 1 of our patients on long-term PD (13) we noticed a slow
steady decline of her Cr levels after converting her from HD to
PD exclusively using biocompatible bicarbonate-containing
low-lactate PD solutions (Figure 1). Concurrently, her lactate
dehydrogenase (LD) gradually dropped from 253 U/L to 216 U/L
(normal < 300 U/L) and the alkaline phosphatase dropped from
405 U/L to 251 U/L (normal range 129 – 417 U/L). Clearly this
is anecdotal, but it is highly consistent with the above concepts
of the pathophysiology of Cr accumulation in PD patients.
CONCLUSIONS
We congratulate Leonid Feldman and the team on their
study and hope to soon learn more about the impact of
elevated Cr levels in CKD, especially in PD patients. As Tonelli
et al. (5) have clearly shown, trace element derangements
in dialysis patients affect outcomes, and perhaps it is prime
time to start monitoring these in our dialysis patients. We also
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(1.23 [0.76 – 1.45] μg/L in fresh and 0.25 [0.22 – 0.44] μg/L
in spent solution), suggesting that PD fluid per se is a potential
source for Cr. As elegantly discussed by the authors, Cr forms a
Cr-lactate complex which is easily absorbed. It is unclear if more
physiologic PD solutions such as Physioneal (Baxter Healthcare
Corporation, Deerfield, IL, USA) or BicaVera (Fresenius Medical
Care, Bad Homburg, Germany), in which lactate exposure is
reduced/absent, would be more favorable from the point of
view of Cr presentation for peritoneal absorption. One of the
major limitations of the study is its lack of water and food Cr
content assessment. The study also did not correlate data such
as erythrocyte stimulating agent needs with Cr levels or any
of the multiple side effects listed below. The authors conclude
that the study adds to the present knowledge by demonstrating
that Cr concentrations are higher in PD patients, and the results
of the 5 patients suggests that the PD fluid was a significant
source of Cr. The authors call for more longitudinal studies and
indeed the measurement of exposure at a single time point
does not allow the time/exposure element of the risk to be
appreciated. The cross-sectional nature of this assessment also
means that batch contamination of PD fluid (all supplied from
a single facility) cannot be ruled out, injecting a little caution
into interpretation of these data necessarily being indicative
of innate differences between dialysis modalities.
For studies measuring metal ion levels such as Cr, an
important consideration is the valency (electron charge) of
these ions. This is especially important with Cr, since it is well
established that the Cr (VI) ion can easily enter cells and is
associated with oxidative stress due to the reduction to Cr (III)
in vivo (10). In contrast, the more commonly found Cr (III)
ion is much less dangerous or may actually be beneficial
(10). Chromium (VI) ion is more carcinogenic and cytotoxic
than the Cr (III) ion (10). It is also unclear what Cr levels
are safe. Most laboratories also do not test the Cr valency.
In fact, chromium lactate is used in nutritional supplements
as a source of chromium (11). In some long-term studies,
investigators assume that Cr (VI) is reduced immediately to
Cr (III), since this happens rapidly ex vivo, but this remains
unproven. The study by Feldman et al. (10) did not measure the
valency of Cr.
It is also unclear whether these high Cr levels are harmful. With oral exposure, Cr has been linked to the following,
although there is little or no information about the valency
(4,12):
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need to establish safe levels in order to assess toxicity. This
could potentially be done by linking cancer data of PD and HD
patients to levels.
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